A network of RNA and protein interactions in Fronto Temporal Dementia

Fontana, Francesca; Siva, Kavitha; Denti, Michela Alessandra

doi:10.3389/fnmol.2015.00009

Cited by 27 publications

(21 citation statements)

References 345 publications

(405 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PPA can be further divided into two main subtypes, semantic variant (svPPA) and non-fluent variant (nfvPPA) [4]. Moreover, (CHMP2B) [5] and, recently, TANK-binding kinase 1 [6].…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia

Grasso

Puopolo

D'Acunto

et al. 2018

JAD

Self Cite

View full text Add to dashboard Cite

Given the heterogeneous nature of frontotemporal dementia (FTD), sensitive biomarkers are greatly needed for the accurate diagnosis of this neurodegenerative disorder. Circulating miRNAs have been reported as promising biomarkers for neurodegenerative disorders and processes affecting the central nervous system, especially in aging. The objective of the study was to evaluate if some circulating miRNAs linked with apoptosis (miR-29b-3p, miR-34a-5p, miR-16-5p, miR-17-5p, miR-107, miR-19b-3p, let-7b-5p, miR-26b-5p, and 127-3p) were able to distinguish between FTD patients and healthy controls. For this study, we enrolled 127 subjects, including 54 patients with FTD, 20 patients with Alzheimer's disease (AD), and 53 healthy controls. The qRT-PCR analysis showed a downregulation of miR-127-3p in FTD compared to controls, while the levels of other miRNAs remained unchanged. Then, miR-127-3p expression was also analyzed in AD patients, finding a different expression between two patient groups. A receiver operating characteristic curve was then created for miR-127-3p to discriminate FTD versus AD (AUC: 0.8986), and versus healthy controls (AUC: 0.8057). In conclusion, miR-127-3p could help to diagnose FTD and to distinguish it from AD.

show abstract

“…PPA can be further divided into two main subtypes, semantic variant (svPPA) and non-fluent variant (nfvPPA) [4]. Moreover, (CHMP2B) [5] and, recently, TANK-binding kinase 1 [6].…”

Section: Introductionmentioning

confidence: 99%

Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia

Grasso

Puopolo

D'Acunto

et al. 2018

JAD

Self Cite

View full text Add to dashboard Cite

show abstract

“…In another recent study, administration of PGRN was suggested as a therapy for AD, based on an inverse dose-dependent relation of PGRN with amyloid load mediated via a PGRNrelated loss of phagocytosis function of the microglial cells [10]. Besides studies into PGRN's pathological mechanism [11], blood and cerebrospinal fluid (CSF) levels of PGRN are extensively studied as markers of FTD, since low blood PGRN levels were found to predict mutations in the PGRN-gene with high sensitivity [12][13][14][15][16][17][18]. Moreover, PGRN is studied as a blood marker for cancer [19] and metabolic disorder pathologies [20].…”

Section: Introductionmentioning

confidence: 99%

Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid

Willemse

Durieux-Lu

Flier

et al. 2016

JAD

View full text Add to dashboard Cite

Abstract. Progranulin (PGRN) levels in blood and cerebrospinal fluid (CSF) are increasingly studied as potential markers for neurodegenerative disorders. We aimed to 1) characterize two commercially available PGRN ELISAs on several assay validation parameters, 2) assess the stability of PGRN in serum and CSF under pre-analytical conditions, and 3) compare stability in the two assays. Intra-and inter-assay variation, inter-lot variation, linearity, lower limit of detection, and kit correlations were assessed for the Adipogen and R&D PGRN ELISA kits. Blood and serum samples were experimentally exposed to ≤9 freeze/thaw cycles, delayed processing for ≤24 h at room temperature and 4• C, and to temperature stability tests for ≤3 weeks at -20• C, 4• C, room temperature, and 37 • C. Both commercial PGRN ELISA kits showed acceptable ranges for intra-and inter-assay variation, where the R&D kit performed more accurate than the Adipogen kit, especially for inter-assay variation (intra-assay serum: 6.7 and 8.3%, respectively; inter-assay serum: 9.2 and 21.0%; intra-assay CSF: 3.6 and 12.0%; inter-assay CSF: 16.0 and 44.5%). Absolute serum PGRN concentrations were 1.9-fold higher in Adipogen than R&D (p < 0.001) and strongly correlated between both kits (ρ = 0.86, p < 0.0001) and CSF PGRN levels were on the borderline of detection in both kits. PGRN was typically stable under all pre-analytical conditions addressed, although two weeks at 37• C resulted in decreased PGRN concentrations in CSF, only when using the Adipogen kit. These results support further examination of PGRN as a potential marker in neurodegenerative diseases, since PGRN is stable in serum and CSF and can be measured using ELISA kits from several providers.

show abstract

“…One of these is miRNA-9; its expression has been found to be reduced in induced-pluripotent-stem-cell-derived neurons of FTD-patients with TDP-43 mutations [56]. TDP-43 is responsible for stabilizing GRN-RNA [57]. On the other hand, and similarly to miRNA-132, in epilepsy (animal model and human) miRNA-9 has shown to be elevated, possibly being proepiletogenic through inhibiting the NFkB1 -transcript and therefore increasing inflammation [58] as well as increasing migration [59].…”

Section: Progranulin and Micrornamentioning

confidence: 99%

Progranulin and Its Related MicroRNAs after Status Epilepticus: Possible Mechanisms of Neuroprotection

Körtvelyessy

Huchtemann

Heinze

et al. 2017

IJMS

View full text Add to dashboard Cite

The current knowledge about neuroprotective mechanisms in humans after status epilepticus is scarce. One reason is the difficulty to measure possible mediators of these neuroprotective mechanisms. The dawn of microRNA detection in the cerebrospinal fluid (CSF) and the recent advancements in measuring proteins in the CSF such as progranulin, which is, e.g., responsible for neurite outgrowth and limiting exceeding neuroinflammatory responses, have given us new insights into putative neuroprotective mechanisms following status epilepticus. This should complement the animal data. In this review, we cover what is known about the role of progranulin as well as the links between microRNA changes and the progranulin pathway following status epilepticus in humans and animals hypothesizing neuroprotective and neurorehabilitative effects. Progranulin has also been found to feature prominently in the neuroprotective processes under hypoxic conditions and initiating neurorehabilitative processes. These properties may be used therapeutically, e.g., through drugs that raise the progranulin levels and therefore the cerebral progranulin levels as well with the goal of improving the outcome after status epilepticus.

show abstract

A network of RNA and protein interactions in Fronto Temporal Dementia

Cited by 27 publications

References 345 publications

Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia

Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia

Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid

Progranulin and Its Related MicroRNAs after Status Epilepticus: Possible Mechanisms of Neuroprotection

Contact Info

Product

Resources

About